V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Coface successfully executed the industrial component of its Fit to Win strategic plan, with an improvement in risk management and operating efficiency. It will present its new plan on 25 February which should be in the same vein as its predecessor in terms of credit insurance, while the group should also want to develop its factoring business. The recent validation of its internal model has increased the group's financial flexibility and it will be able to maintain a favourable polic...
Coface a exécuté avec succès le volet industriel de son plan stratégique Fit to Win avec notamment une amélioration de la gestion des risques et de l’efficacité opérationnelle. Il présentera le 25 février son nouveau plan, qui devrait être dans la continuité en ce qui concerne l’assurance-crédit, alors que Coface devrait vouloir développer ses activités d’affacturage. La validation récente de son modèle interne a augmenté la flexibilité financière du groupe, qui pourra maintenir une p...
>Two products acquired from Elanco for $ 140m - Vétoquinol announced yesterday evening it signed an agreement to acquire the European and UK rights to the Profender® and Drontal® product families from Elanco Animal Health for a total price of $ 140m in an all-cash deal. Under the terms of the deal, Vetoquinol will acquire the Profender® and Drontal® products, intellectual property, registrations and other rights currently held by Bayer AG animal health in Europe ...
The general evaluation of ZIX CORP. (US), a company active in the Computer Services industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 18, 2020, the closing price was USD 7.34 and its potential was estimated at USD 9.06.
ZAI LAB ADR.LTD. (US), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date February 18, 2020, the closing price was USD 61.10 and its potential was estimated at USD 64.16.
The independent financial analyst theScreener just lowered the general evaluation of SPIRIT AIRLINES INCO. (US), active in the Airlines industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 18, 2020, the closing price was USD 42.59 and its target price was estimated at USD 34.08.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.